Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
AI-Guided Cancer Vaccines Signal a New Era in Personalized Medicine
/in Artificial Intelligence, Immunotherapy, Preclinical Research/by MaxPhase 1: China Approves Groundbreaking Drug for Bone Metastases SKB107
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Started: Pocenbrodib Update
/in Clinical Trial, Metastatic, Phase 1/by MaxRedefining Prostate Cancer Care: The LIBERTAS Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxTelomir-1: Innovative Molecule Slows Tumor Growth and Reduces Chemotherapy Toxicity
/in Preclinical Research/by MaxPhase I Clinical Trial of AZD2284, AZD2287, and AZD2275
/in Clinical Trial, Metastatic, Phase 1/by MaxBreaking Resistance: A Dual-Pathway Drug Shows Promise for Advanced Prostate Cancer
/in Preclinical Research/by MaxEnzalutamide Boosts PSA Control in High-Risk Prostate Cancer: Insights from the EMBARK Trial
/in Post-hoc, Retrospective studies/by Max